Apeptico Forschung Und Entwicklung Gmbh

University of Miami

Innogenetics N.v.

Augusta University Research Institute, Inc.

Rudolf Lucas

Bernhard Fischer

Hendrik Fischer

Andrew V Schally

Patrick De Baetselier

Susan Jane Tzotzos

Maritza Romero-Lucas

Neal Weintraub

Jérôme Pugin

Alain Bloc

Lucie Fransen

Susan Tzotzos

A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.

Method for preventing and treating hyperpermeability

Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, where X, X, and Xcan be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.

Composition comprising a peptide and an inhibitor of viral neuraminidase

Cyclic peptide of formula whereinXcomprises an amino acid (sequence), with 1 to 4 members, comprising natural and unnatural amino acids, and Xcomprises a natural amino acid, and wherein Xcomprises the N-terminal amino acid left in position 1, and Xthe C-terminal amino acid in the ultimate, right position, in the form of a lyophilisate without additives and/or stabilizers and its use.

Lyophilisate containing a cyclic peptide of formula X-GQRETPEGAEAKPWY-X

Described is a composition comprising&#x2014;a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, where X, Xand Xcan be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and&#x2014;an inhibitor of viral neuraminidase.

Described herein are materials and methods for treating dyslipidemia in a mammalian subject in need thereof comprising administering a growth hormone-releasing hormone (GHRH) antagonist or variant thereof to the subject.

Materials and methods of treating dyslipidemia

What is described is a peptide which consists of 7-20, especially 7-17, adjacent amino acids and comprises the hexamer TXEXXE where X, Xand Xmay be any natural or unnatural amino acid, where the peptide does not have any TNF receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.

Pharmaceutical composition for treatment of the pulmonary form of altitude sickness caused by lack of oxygen and reduced air pressure

A peptide consisting of 7-17 amino acids and including the adjacent hexamer TXEXXE, where X, Xand Xcan be any natural or non natural amino acid, wherein the peptide does not exhibit TNF-receptor-binding activity and is cyclic, for the treatment or prevention of vascular complications in diabetes patients.

Treatment of vascular complications of diabetes

A cyclic organic compound which comprises 16 amino acids or 17 amino acids and has no carboxyl group C-terminally and/or no amino group N-terminally. Optionally, one of the amino acids is a nonnatural amino acid. The ring closure is formed between a side chain of one amino acid and the C-terminus of another amino acid, or the ring closure is effected with the aid of a nonnatural amino acid. A process for producing and using the compound for regulating vectorial ion channels, for treating diseases associated with the lung function and for treating oedemas is provided.

Organic compound for the regulation of vectorial ion channels

A protein selected from the amino acid sequence of the region valine Val(91) to glycine Gly(121) of the mature human tumor necrosis factor, or a portion thereof, with the proviso that the protein comprises at least the amino acid sequence of the region lysine Lys(98) to glutamic acid Glu(116), with the cysteine Cys(101) being replaced by a glycine and an amide bond being formed between the amino group of the side chain of the lysine Lys(98) and the carboxyl group of the side chain of the glutamic acid Glu(116), which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.

Cyclic, cystein-free protein

A protein which is composed N-terminally of one or several C-terminal parts of the amino acid sequence of the mature tumor necrosis factor and C-terminally of one or several N-terminal parts of the amino acid sequence of the mature tumor necrosis factor, which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.

Reverse protein

The present invention is based on the finding that peptides derived from a specific domain of tumor necrosis factor-alpha (TNF-&#x3b1;) can efficiently be used to treat oedema. More specifically, the present invention relates to the usage of peptides derived from the region of human TNF-&#x3b1; from Serto Gluto treat pulmonary oedema. For example, the circularized peptide having amino acid sequence CGQRETPEGAEAKPWYC is shown to be very efficient in inducing oedema resorption.

Growing community of inventors

Aartselaar, Belgium

Rudolf Lucas